These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 7788039

  • 1. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG, Papageorgiou AA, Avramidis MJ, Kontopoulos AG.
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [Abstract] [Full Text] [Related]

  • 2. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 3. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.
    Circulation; 2006 Mar 28; 113(12):1556-63. PubMed ID: 16534013
    [Abstract] [Full Text] [Related]

  • 4. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N.
    Indian Heart J; 2003 Mar 28; 55(3):234-40. PubMed ID: 14560932
    [Abstract] [Full Text] [Related]

  • 5. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V.
    N Engl J Med; 1987 Nov 12; 317(20):1237-45. PubMed ID: 3313041
    [Abstract] [Full Text] [Related]

  • 6. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M, McNicoll S, Marcil M, Connelly P, Lussier-Cacan S, Davignon J, Latour Y, Genest J.
    Can J Cardiol; 1997 Mar 12; 13(3):253-60. PubMed ID: 9117913
    [Abstract] [Full Text] [Related]

  • 7. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR, Garrett BC, King SB, Momary KM, Chronos NA, Wood PD.
    Am J Cardiol; 2009 Feb 01; 103(3):387-92. PubMed ID: 19166694
    [Abstract] [Full Text] [Related]

  • 8. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
    Connelly PW, Stachenko S, MacLean DR, Petrasovits A, Little JA.
    Can J Cardiol; 1999 Apr 01; 15(4):419-27. PubMed ID: 10322251
    [Abstract] [Full Text] [Related]

  • 9. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 01; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 10. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F, Ok E, Duman S, Kürsad S, Unsal A, Alev M, Atabay G, Basçi A.
    Adv Perit Dial; 1996 Oct 01; 12():261-5. PubMed ID: 8865916
    [Abstract] [Full Text] [Related]

  • 11. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.
    Arterioscler Thromb Vasc Biol; 2008 Jun 01; 28(6):1172-8. PubMed ID: 18356553
    [Abstract] [Full Text] [Related]

  • 13. [The Göttingen Risk, Incidence and Prevalence (GRIPS) study. Recommendations for the prevention of coronary heart disease].
    Cremer P, Muche R.
    Ther Umsch; 1990 Jun 01; 47(6):482-91. PubMed ID: 2375005
    [Abstract] [Full Text] [Related]

  • 14. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 01; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M, Sertić J, Duraković Z.
    Acta Med Croatica; 2001 Feb 01; 55(4-5):161-7. PubMed ID: 12398019
    [Abstract] [Full Text] [Related]

  • 16. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M.
    J Physiol Pharmacol; 2001 Aug 01; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [Abstract] [Full Text] [Related]

  • 17. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD.
    Am J Cardiol; 2005 Nov 01; 96(9):1266-72. PubMed ID: 16253595
    [Abstract] [Full Text] [Related]

  • 18. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
    Real JT, Chaves FJ, Martínez-Usó I, García-García AB, Ascaso JF, Carmena R.
    Eur Heart J; 2001 Mar 01; 22(6):465-71. PubMed ID: 11237541
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 20. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
    Wilt TJ, Rubins HB, Collins D, O'Connor TZ, Rutan GH, Robins SJ.
    Arch Intern Med; 1996 Jun 10; 156(11):1181-8. PubMed ID: 8639012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.